Intensive Glycemic Control and Cardiovascular Disease: Are There Patients Who May Benefit?

References

• . National Diabetes Education Program. http://ndep.nih.gov/diabets-facts/. Accessed October 1, 2011
   Google Scholar
• . National Diabetes Statistics 2011. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed October 1, 2011
   Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23( suppl 2):B21–B29
   PubMed Web of Science ®Google Scholar
• . Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998; 158(2):134–140
   PubMedGoogle Scholar
• . Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996; 124(1 pt 2):90–96
   PubMedGoogle Scholar
• . Ohkubo Y, Kishikawa H, Araki E, . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28(2):103–117
   PubMed Web of Science ®Google Scholar
• . Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington R P, et al.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, . VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Reaven PD, Moritz TE, Schwenke DC, ; Veterans Affairs Diabetes Trial. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009; 58(11):2642–2648
   PubMed Web of Science ®Google Scholar
• . Chokrungvaranon NK, Bahn J, Reda G, ; VADT study group. Ability of indicies of cardiovascular disease (CVD) risk and comorbidity to predict CVD outcomes with intensive glucose control in the VADT. Abstract. Diabetes. 2011; 60( suppl 1):A9, 34–0R
   PubMedGoogle Scholar
• . Greenfeld S, Billimek J, Pellegrini F, . Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: A cohort study. Ann Intern Med. 2009; 151(12):854–860
   PubMedGoogle Scholar
• . Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999; 22(2):233–240
   PubMed Web of Science ®Google Scholar
• . Khaw KT, Wareham N, Luben R, . Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001; 322(7277):15–18
   PubMed Web of Science ®Google Scholar
• . Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004; 141(6):413–420
   PubMed Web of Science ®Google Scholar
• . Selvin E, Marinopoulos S, Berkenblit G, . Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141(6):421–431
   PubMed Web of Science ®Google Scholar
• . Ismail-Beigi F, Craven T, Banerji MA, ; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010; 376(9739):419–430
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Cleary PA, Backlund JY, . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643–2653
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970; 19( suppl):789–830
   PubMed Web of Science ®Google Scholar
• . Leibel B. An analysis of the University Group Diabetes Study Program: Data results and conslusions. Can Med Assoc J. 1971; 105(3):292–294
   PubMedGoogle Scholar
• . Sulfonylureas: Effects in vivo and in vitro. Ann Intern Med. 1971; 75(4):607–621
   PubMedGoogle Scholar
• . Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C. Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. J Diabetes Complications. 2005; 19(4):207–211
   PubMed Web of Science ®Google Scholar
• . Duckworth WA, Moritz C; VADT investigators. VA Diabetes Trial (VADT) update. Presented at: American Diabetes Association 69th Scientifc Session; June 5–9, 2009; New Orleans, LA
   Google Scholar
• . Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40(5):373–383
   PubMedGoogle Scholar
• . Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006; 295(7):801–808
   PubMed Web of Science ®Google Scholar
• . Turnbull FM, Abraira C, Anderson RJ, . Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52(11):2288–2298
   PubMed Web of Science ®Google Scholar
• . Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L; Euro Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: A report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008; 29(2):177–184
   PubMed Web of Science ®Google Scholar
• . Lenzen M, Ryden L, Ohrvik J, . Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: A report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006; 27(24):2969–2974
   PubMedGoogle Scholar
• . Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: A decision analysis. Ann Intern Med. 2008; 149(1):11–19
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J Clin Endocrinol Metab. 2009; 94(8):2751–2756
   PubMedGoogle Scholar
• . Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009; 94(2): 410–415
   PubMed Web of Science ®Google Scholar
• . Ceriello A. Hypothesis: The “metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract. 2009; 86( suppl 1):S2–S6
   PubMed Web of Science ®Google Scholar
• . Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation. 2006; 114(6):597–605
   PubMed Web of Science ®Google Scholar
• . Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010; 106(5):842–853
   PubMed Web of Science ®Google Scholar
• . Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: Round and round we go [published online ahead of print October 19, 2010]. Amino Acids.
   Google Scholar
• . Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995; 15(5):551–561
   PubMed Web of Science ®Google Scholar
• . Ashcroft GS, Mills SJ, Ashworth JJ. Ageing and wound healing. Biogerontology. 2002; 3(6):337–345
   PubMed Web of Science ®Google Scholar
• . Silverman EM, Silverman AG. Granulocyte adherence in the elderly. Am J Clin Pathol. 1977; 67(1):49–52
   PubMedGoogle Scholar
• . Ashcroft GS, Horan MA, Ferguson M W. Aging alters the inflammatory and endothelial cell adhesion molecule profiles during human cutaneous wound healing. Lab Invest. 1998; 78(1):47–58
   PubMedGoogle Scholar
• . Standards of medical care in diabetes—2011. Diabetes Care. 2011; 34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicans. Glycemic control and type 2 diabetes mellitus: The optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007; 147(6):417–422
   PubMed Web of Science ®Google Scholar
• . Rodbard H W, Blonde L, Braithwaite SS, ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13( suppl 1):1–68
   PubMedGoogle Scholar
• . Eldor R, Raz I. The individualized target HbA1c: A new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud. 2009; 6(1):6–12
   PubMedGoogle Scholar
• . Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: Implications of recent clinical trials. Ann Intern Med. 2011; 154(8):554–559
   PubMed Web of Science ®Google Scholar
• . Raz I, Wilson P W, Strojek K, . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial. Diabetes Care. 2009; 32(3):381–386
   PubMed Web of Science ®Google Scholar